Form 4: Ligand Pharmaceuticals CEO Exercises Stock Options, Boosting Holdings

CEO Todd C. Davis exercised stock options on March 25, 2024, increasing his direct ownership of Ligand Pharmaceuticals' common stock.

Summary

• On March 25, 2024, Todd C. Davis, CEO of Ligand Pharmaceuticals, exercised non-qualified stock options to acquire common stock.
• The transactions involved the exercise of options at prices of $46.2, $67.24, $68.51, and $66.19.
• These exercises resulted in the acquisition of 7,448, 2,855, 2,156, and 3,556 shares, respectively.
• Following these transactions, Davis directly owns 120,160 shares of Ligand Pharmaceuticals' common stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting the facts of the stock option exercises. It doesn't contain overtly positive or negative information.

Positives

• The CEO's decision to exercise stock options could be interpreted as a sign of confidence in the company's future performance.

Industry Context

Stock option exercises are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The specific terms and conditions of these options, such as vesting schedules and exercise prices, can vary widely based on company performance and industry standards.

Stakeholder Impact

• The CEO's increased stake in the company could potentially reassure shareholders.

Key Dates